These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27354233)

  • 1. Biosimilars: Extrapolation for oncology.
    Curigliano G; O'Connor DP; Rosenberg JA; Jacobs I
    Crit Rev Oncol Hematol; 2016 Aug; 104():131-7. PubMed ID: 27354233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars are coming: ready or not.
    Zalcberg J
    Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
    Agarwal AB; McBride A
    Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rise of oncology biosimilars: from process to promise.
    Verrill M; Declerck P; Loibl S; Lee J; Cortes J
    Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars and the extrapolation of indications for inflammatory conditions.
    Tesser JR; Furst DE; Jacobs I
    Biologics; 2017; 11():5-11. PubMed ID: 28255229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of biosimilars in oncology.
    Schellekens H; Smolen JS; Dicato M; Rifkin RM
    Lancet Oncol; 2016 Nov; 17(11):e502-e509. PubMed ID: 27819248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
    MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biosimilar drugs in oncology].
    Levêque D
    Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M; Wolff-Holz E
    Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.